Evidence map›Paper›PMID 34974814›Full record

ArticleBioengineered2022

Prostate-specific membrane antigen modulates the progression of prostate cancer by regulating the synthesis of arginine and proline and the expression of androgen receptors and Fos proto-oncogenes.

Xi Hong, Liang Mao, Luwei Xu, Qiang Hu, Ruipeng Jia

Open access · goldAbstract read
In one paragraph

Article in Bioengineered, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. PSMA-617 inhibits proliferation and potentiates theNaunyn-Schmiedeberg's archives of pharmacology · 2023
    Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Xi HongDepartment of Urology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.ORCID 0000-0002-9565-1919
Liang MaoDepartment of Urology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Luwei XuDepartment of Urology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Qiang HuDepartment of Urology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Ruipeng JiaDepartment of Urology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Nanjing Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The expression of prostate-specific membrane antigen (PSMA) is strikingly upregulated during oncogenesis and prostate cancer (PCa) progression, but the functions of this antigen in PCa remain unclear. Here, we constructed PSMA-knockdown LNCaP and 22rv1 cell lines and performed metabonomic and transcriptomic analyses to determine the effects of PSMA on PCa metabolism and transcription. The metabolism of arginine and proline was detected using specific kits. The mRNA and protein expression levels of the identified differentially expressed genes were quantified by RT-qPCR and Western blotting. The proliferation of each cell line was evaluated through CCK-8, EdU and colony formation assays. The migration and invasion abilities of each cell line were detected using wound healing and transwell assays, respectively. PSMA knockdown led to metabolic disorder and abnormal transcription in PCa and resulted in inhibition of the proliferation and metastasis of PCa cells in vitro and in vivo. The depletion of PSMA also promoted the biosynthesis of arginine and proline, inhibited the expression of AR and PSA, and induced the expression of c-Fos and FosB. PSMA plays an important role in the metabolism, proliferation and metastasis of human PCa and may be a promising therapeutic target.

Indexed as

AnimalsAntigens, SurfaceArginineCell Line, TumorCell MovementCell ProliferationGene Expression ProfilingGene Expression Regulation, NeoplasticGene Knockdown TechniquesGlutamate Carboxypeptidase IIHumansMaleMetabolomicsMiceNeoplasm TransplantationProlineAntigens, SurfaceArginineAR protein, humanFOLH1 protein, humanFOSB protein, humanFOS protein, humanGlutamate Carboxypeptidase IIProlineProto-Oncogene Proteins c-fosReceptors, Androgenandrogen receptorargininec-Fosprostate cancerPSMA

Identifiers

PMID34974814
PMCPMC8805960
OpenAlexW4206729433

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.